Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ce-245677. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.53 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | RET | P07949 | 4/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ce-245677 SCHEMBL29392014 | 1.00 | PDGFRB (0.61) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5316388 | 0.97 | PDGFRB (0.58) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5458170 | 0.97 | PDGFRB (0.58) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5457086 | 0.92 | PDGFRB (0.55) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL1941041 | 0.92 | PDGFRB (0.60) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| Ce-245677 SCHEMBL5428869 | 0.92 | PDGFRB (0.52) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL14339404 | 0.91 | PDGFRB (0.49) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL1941202 | 0.91 | PDGFRB (0.73) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL14339406 | 0.90 | PDGFRB (0.64) | PDGFRBNTRK2NTRK1NTRK3EGFR | |
| SCHEMBL1941712 | 0.90 | PDGFRB (0.64) | PDGFRBNTRK2NTRK1NTRK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | claimed |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | PFIZER INC | 2007-12-13 | — | — | US | claimed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | claimed |
| WO-2007066189-A2 | SALTS, PRODRUGS AND FORMULATIONS OF 1-[5-(4-AMINO-7-ISOPROPYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONYL)-2-METHOXY-PHENYL]-3-(2,4-DICHLORO-PHENYL)-UREA | PFIZER PRODUCTS INC. (US) | 2007-06-14 | — | — | WO | claimed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | claimed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2007066189-A3 | SALTS, PRODRUGS AND FORMULATIONS OF 1-[5-(4-AMINO-7-ISOPROPYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONYL)-2-METHOXY-PHENYL]-3-(2,4-DICHLORO-PHENYL)-UREA | PFIZER PROD INC (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | PFIZER INC | 2007-12-13 | — | — | US | disclosed |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | PFIZER INC | 2007-12-13 | — | — | US | disclosed |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | PFIZER INC | 2007-12-13 | — | — | US | disclosed |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | PFIZER INC | 2007-12-13 | — | — | US | disclosed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2007066189-A2 | SALTS, PRODRUGS AND FORMULATIONS OF 1-[5-(4-AMINO-7-ISOPROPYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONYL)-2-METHOXY-PHENYL]-3-(2,4-DICHLORO-PHENYL)-UREA | PFIZER PRODUCTS INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007066189-A2 | SALTS, PRODRUGS AND FORMULATIONS OF 1-[5-(4-AMINO-7-ISOPROPYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONYL)-2-METHOXY-PHENYL]-3-(2,4-DICHLORO-PHENYL)-UREA | PFIZER PRODUCTS INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | CCNA1, CCNT1, TP53 | TEK 1536/4885PDGFRB 2465/4885NTRK2 4651/4885 |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | CDKN1A, DPYD, SLC14A1 | TEK 2301/4885PDGFRB 3365/4885NTRK2 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.